Compare
Recursion Pharmaceuticals, Inc. vs Autolus Therapeutics plc vs Vir Biotechnology, Inc. vs MeiraGTx Holdings plc
| Latest fiscal year | Recursion Pharmaceuticals, Inc. RXRX | Autolus Therapeutics plc AUTL | Vir Biotechnology, Inc. VIR | MeiraGTx Holdings plc MGTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $74.68M | $75.39M | $68.56M | $81.39M |
| Revenue growth (YoY) | +26.9% | +644.9% | -7.6% | +144.6% |
| Gross margin | 5.0% (computed) | -27.8% (computed) | n/a | n/a |
| Operating margin | -867.9% | -358.9% | -699.2% | -130.2% |
| Net margin | -863.4% | -381.4% | -638.9% | -140.3% |
| Net income | -$644.76M | -$287.53M | -$437.99M | -$114.20M |
| EPS (Diluted) | -$1.44 | -$1.08 | -$3.16 | -$1.42 |
| Operating cash flow | -$371.81M | -$283.57M | -$391.78M | -$46.36M |
| Free cash flow | -$378.28M | -$302.61M | -$396.61M | -$50.19M |
| Cash & equivalents | $743.29M | $104.13M | $232.19M | $65.93M |
| Total assets | $1.47B | $589.07M | $1.00B | $244.43M |
| Total liabilities | $343.26M | $410.94M | $237.55M | $250.22M |
| Shareholders' equity | $1.13B | $178.13M | $765.28M | -$5.79M |
| Return on year-end equity | -57.0% | -161.4% | -57.2% | n/a |
| Shares outstanding | 528.18M | n/a | 139.47M | 81.12M |
Revenue, most recent five fiscal years
| Fiscal year | Recursion Pharmaceuticals, Inc. | Autolus Therapeutics plc | Vir Biotechnology, Inc. | MeiraGTx Holdings plc |
|---|---|---|---|---|
| Latest | $74.68M Ended 2025-12-31 | $75.39M Ended 2025-12-31 | $68.56M Ended 2025-12-31 | $81.39M Ended 2025-12-31 |
| 1 year earlier | $58.84M Ended 2024-12-31 | $10.12M Ended 2024-12-31 | $74.20M Ended 2024-12-31 | $33.28M Ended 2024-12-31 |
| 2 years earlier | $44.58M Ended 2023-12-31 | $1.70M Ended 2023-12-31 | $86.18M Ended 2023-12-31 | $14.02M Ended 2023-12-31 |
| 3 years earlier | $39.84M Ended 2022-12-31 | n/a | $1.62B Ended 2022-12-31 | n/a |
| 4 years earlier | $10.18M Ended 2021-12-31 | n/a | $1.10B Ended 2021-12-31 | n/a |